News

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

Rhino-orbital-cerebral mucormycosis, a life-threatening fungal infection, typically occurs in patients with diabetes

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa.

The platform, developed by University College London and Heidelberg Engineering, demonstrated accuracy and precision in early tests.

Findings from a phase 2 clinical trial support the therapeutic potential of ADX-2191 in patients with retinitis pigmentosa

Vonaprument has received fast track designation from the US Food and Drug Administration.

Australian researchers highlighted the overlooked ocular risks surfers and divers face from UV and blue light exposure.

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization in ophthalmology research.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

The nitric oxide-donating bimatoprost therapy is intended to lower intraocular pressure in patients with glaucoma or ocular hypertension

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting the need for further research in training datasets.

Ocular Therapeutix to showcase its drug delivery solutions at upcoming ophthalmology conferences.

Eyetronic is a noninvasive treatment for glaucoma that provides external neural stimulation to the optic nerve of patients.

The SYD-101 atropine formulation is licensed by Santen SA, based in Switzerland, from Sydnexis Inc, based in California

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting the need for further research in training datasets.

President Joel S. Schuman, MD, highlights the group’s mission and vision for the future—uniting 17 working groups and over 80 stakeholders.

These updates support Ocugen in its efforts to pursue its goal of 3 biologics license applications (BLA) in the next 3 years.

To mark Ophthalmology Times' 50th anniversary, we invited top experts to reflect on the most significant innovations in ophthalmology over the past five decades.

The primary end point of the trial was complete resolution of debris after 6 weeks of twice-daily dosing.

Funding will be specifically used to accelerate the clinical development of urcosimod (formerly called OK-101).

The law will work to remove outdated restrictions on medications and allow some in-office procedures and will take effect in August.

Pinguecula is a benign, common degeneration of the conjunctiva that appears as a grey-white-yellow mass on the bulbar conjunctiva.